STING1 and cancer: The innate immune response is muted in several cancers [12,13] and so the demonstration that the activation of STING by CDNs or the small molecule DMXAA leads to significant tumor regression in murine models has led to a flurry of activity directed towards the discovery of STING agonists [14].